Thang M. Luong

Xiangning Chen, Chen Liang, Da Huang et al. · cmu, deepmind

We present a method to formulate algorithm discovery as program search, and apply it to discover optimization algorithms for deep neural network training. We leverage efficient search techniques to explore an infinite and sparse program space. To bridge the large generalization gap between proxy and target tasks, we also introduce program selection and simplification strategies. Our method discovers a simple and effective optimization algorithm, $\textbf{Lion}$ ($\textit{Evo$\textbf{L}$ved S$\textbf{i}$gn M$\textbf{o}$me$\textbf{n}$tum}$). It is more memory-efficient than Adam as it only keeps track of the momentum. Different from adaptive optimizers, its update has the same magnitude for each parameter calculated through the sign operation. We compare Lion with widely used optimizers, such as Adam and Adafactor, for training a variety of models on different tasks. On image classification, Lion boosts the accuracy of ViT by up to 2% on ImageNet and saves up to 5x the pre-training compute on JFT. On vision-language contrastive learning, we achieve 88.3% $\textit{zero-shot}$ and 91.1% $\textit{fine-tuning}$ accuracy on ImageNet, surpassing the previous best results by 2% and 0.1%, respectively. On diffusion models, Lion outperforms Adam by achieving a better FID score and reducing the training compute by up to 2.3x. For autoregressive, masked language modeling, and fine-tuning, Lion exhibits a similar or better performance compared to Adam. Our analysis of Lion reveals that its performance gain grows with the training batch size. It also requires a smaller learning rate than Adam due to the larger norm of the update produced by the sign function. Additionally, we examine the limitations of Lion and identify scenarios where its improvements are small or not statistically significant. Lion is also successfully deployed in production systems such as Google search ads CTR model.

Jiahui Yu, Yuanzhong Xu, Jing Yu Koh et al. · cmu

We present the Pathways Autoregressive Text-to-Image (Parti) model, which generates high-fidelity photorealistic images and supports content-rich synthesis involving complex compositions and world knowledge. Parti treats text-to-image generation as a sequence-to-sequence modeling problem, akin to machine translation, with sequences of image tokens as the target outputs rather than text tokens in another language. This strategy can naturally tap into the rich body of prior work on large language models, which have seen continued advances in capabilities and performance through scaling data and model sizes. Our approach is simple: First, Parti uses a Transformer-based image tokenizer, ViT-VQGAN, to encode images as sequences of discrete tokens. Second, we achieve consistent quality improvements by scaling the encoder-decoder Transformer model up to 20B parameters, with a new state-of-the-art zero-shot FID score of 7.23 and finetuned FID score of 3.22 on MS-COCO. Our detailed analysis on Localized Narratives as well as PartiPrompts (P2), a new holistic benchmark of over 1600 English prompts, demonstrate the effectiveness of Parti across a wide variety of categories and difficulty aspects. We also explore and highlight limitations of our models in order to define and exemplify key areas of focus for further improvements. See https://parti.research.google/ for high-resolution images.

Thang Luong, Dawsen Hwang, Hoang H. Nguyen et al.

Finding the right north-star metrics is highly critical for advancing the mathematical reasoning capabilities of foundation models, especially given that existing evaluations are either too easy or only focus on getting correct short answers. To address these issues, we present IMO-Bench, a suite of advanced reasoning benchmarks, vetted by a panel of top specialists and that specifically targets the level of the International Mathematical Olympiad (IMO), the most prestigious venue for young mathematicians. IMO-AnswerBench first tests models on 400 diverse Olympiad problems with verifiable short answers. IMO-Proof Bench is the next-level evaluation for proof-writing capabilities, which includes both basic and advanced IMO level problems as well as detailed grading guidelines to facilitate automatic grading. These benchmarks played a crucial role in our historic achievement of the gold-level performance at IMO 2025 with Gemini Deep Think (Luong and Lockhart, 2025). Our model achieved 80.0% on IMO-AnswerBench and 65.7% on the advanced IMO-Proof Bench, surpassing the best non-Gemini models by large margins of 6.9% and 42.4% respectively. We also showed that autograders built with Gemini reasoning correlate well with human evaluations and construct IMO-GradingBench, with 1000 human gradings on proofs, to enable further progress in automatic evaluation of long-form answers. We hope that IMO-Bench will help the community towards advancing robust mathematical reasoning and release it at https://imobench.github.io/.

Tai Dang, Long-Hung Pham, Sang T. Truong et al.

Despite decades of advancements in automated ligand screening, large-scale drug discovery remains resource-intensive and requires post-processing hit selection, a step where chemists manually select a few promising molecules based on their chemical intuition. This creates a major bottleneck in the virtual screening process for drug discovery, demanding experts to repeatedly balance complex trade-offs among drug properties across a vast pool of candidates. To improve the efficiency and reliability of this process, we propose a novel human-centered framework named CheapVS that allows chemists to guide the ligand selection process by providing preferences regarding the trade-offs between drug properties via pairwise comparison. Our framework combines preferential multi-objective Bayesian optimization with a docking model for measuring binding affinity to capture human chemical intuition for improving hit identification. Specifically, on a library of 100K chemical candidates targeting EGFR and DRD2, CheapVS outperforms state-of-the-art screening methods in identifying drugs within a limited computational budget. Notably, our method can recover up to 16/37 EGFR and 37/58 DRD2 known drugs while screening only 6% of the library, showcasing its potential to significantly advance drug discovery.